An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder

Christopher J Kratochvil, D. Bohac, M. Harrington, N. Baker, D. May, W. J. Burke

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Objective: To collect pilot data assessing the safety, tolerability, and efficacy of tomoxetine, a nonstimulant norepinephrine enhancer, in pediatric attention deficit hyperactivity disorder (ADHD). Methods: An open-label trial of tomoxetine in pediatric ADHD was conducted as part of a multisite clinical trial. Following a baseline assessment, an ascending dose titration was completed during 10 weekly visits. Results: Ten subjects were enrolled at baseline, with eight completing the study. Seven of the eight remaining subjects met efficacy criteria. Significant decreases in symptom severity ratings by parents and study investigators were found. The medication was well tolerated, with transient appetite suppression the most frequently reported side effect. However, subjects' weights remained stable across study visits. Discussion: These preliminary findings suggest that tomoxetine may hold promise as a treatment for pediatric ADHD. ɫ 2001 Mary Ann Liebert, Inc.

Original languageEnglish (US)
Pages (from-to)167-170
Number of pages4
JournalJournal of Child and Adolescent Psychopharmacology
Volume11
Issue number2
DOIs
StatePublished - Jan 1 2001

Fingerprint

Attention Deficit Disorder with Hyperactivity
Pediatrics
Appetite
Norepinephrine
Research Personnel
Clinical Trials
Safety
Weights and Measures
Atomoxetine Hydrochloride
Therapeutics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder. / Kratochvil, Christopher J; Bohac, D.; Harrington, M.; Baker, N.; May, D.; Burke, W. J.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 11, No. 2, 01.01.2001, p. 167-170.

Research output: Contribution to journalArticle

Kratochvil, Christopher J ; Bohac, D. ; Harrington, M. ; Baker, N. ; May, D. ; Burke, W. J. / An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder. In: Journal of Child and Adolescent Psychopharmacology. 2001 ; Vol. 11, No. 2. pp. 167-170.
@article{01b375b15cad429ea9a3787c94672768,
title = "An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder",
abstract = "Objective: To collect pilot data assessing the safety, tolerability, and efficacy of tomoxetine, a nonstimulant norepinephrine enhancer, in pediatric attention deficit hyperactivity disorder (ADHD). Methods: An open-label trial of tomoxetine in pediatric ADHD was conducted as part of a multisite clinical trial. Following a baseline assessment, an ascending dose titration was completed during 10 weekly visits. Results: Ten subjects were enrolled at baseline, with eight completing the study. Seven of the eight remaining subjects met efficacy criteria. Significant decreases in symptom severity ratings by parents and study investigators were found. The medication was well tolerated, with transient appetite suppression the most frequently reported side effect. However, subjects' weights remained stable across study visits. Discussion: These preliminary findings suggest that tomoxetine may hold promise as a treatment for pediatric ADHD. ɫ 2001 Mary Ann Liebert, Inc.",
author = "Kratochvil, {Christopher J} and D. Bohac and M. Harrington and N. Baker and D. May and Burke, {W. J.}",
year = "2001",
month = "1",
day = "1",
doi = "10.1089/104454601750284072",
language = "English (US)",
volume = "11",
pages = "167--170",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder

AU - Kratochvil, Christopher J

AU - Bohac, D.

AU - Harrington, M.

AU - Baker, N.

AU - May, D.

AU - Burke, W. J.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Objective: To collect pilot data assessing the safety, tolerability, and efficacy of tomoxetine, a nonstimulant norepinephrine enhancer, in pediatric attention deficit hyperactivity disorder (ADHD). Methods: An open-label trial of tomoxetine in pediatric ADHD was conducted as part of a multisite clinical trial. Following a baseline assessment, an ascending dose titration was completed during 10 weekly visits. Results: Ten subjects were enrolled at baseline, with eight completing the study. Seven of the eight remaining subjects met efficacy criteria. Significant decreases in symptom severity ratings by parents and study investigators were found. The medication was well tolerated, with transient appetite suppression the most frequently reported side effect. However, subjects' weights remained stable across study visits. Discussion: These preliminary findings suggest that tomoxetine may hold promise as a treatment for pediatric ADHD. ɫ 2001 Mary Ann Liebert, Inc.

AB - Objective: To collect pilot data assessing the safety, tolerability, and efficacy of tomoxetine, a nonstimulant norepinephrine enhancer, in pediatric attention deficit hyperactivity disorder (ADHD). Methods: An open-label trial of tomoxetine in pediatric ADHD was conducted as part of a multisite clinical trial. Following a baseline assessment, an ascending dose titration was completed during 10 weekly visits. Results: Ten subjects were enrolled at baseline, with eight completing the study. Seven of the eight remaining subjects met efficacy criteria. Significant decreases in symptom severity ratings by parents and study investigators were found. The medication was well tolerated, with transient appetite suppression the most frequently reported side effect. However, subjects' weights remained stable across study visits. Discussion: These preliminary findings suggest that tomoxetine may hold promise as a treatment for pediatric ADHD. ɫ 2001 Mary Ann Liebert, Inc.

UR - http://www.scopus.com/inward/record.url?scp=0034960305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034960305&partnerID=8YFLogxK

U2 - 10.1089/104454601750284072

DO - 10.1089/104454601750284072

M3 - Article

C2 - 11436956

AN - SCOPUS:0034960305

VL - 11

SP - 167

EP - 170

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 2

ER -